Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 9-14

  Peng, Xiaomei ^a   Ascher Svanum, Haya ^a   Faries, Douglas ^a   Conley, Robert R ^a   Schuh, Kory J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Claims database; Depot antipsychotics; Mirror image; Treatment outcomes

Indexed keywords

FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CHRONIC LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 79952972444     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S16061     Document Type: Article

References (22)

1. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
2. Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68:1163-1171.
3. Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat. 2007;3:13-39.
4. Weiden P, Zygmunt A. Medication noncompliance in schizophrenia. Part I. Assessment. J Pract Psychiatry Behav Health. 1997;3:106-110.
5. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196-201.
6. Simpson GM. A brief history of depot neuroleptics. J Clin Psychiatry. 1998;45:3-4.
7. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs. 1994;47:741-773.
8. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 1998;8:55-66.
9. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58:482-488.
10. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic longacting injections vs oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl. 2009;52:S20-S28.
11. Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol. 2008;22:128-131.
12. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirrorimage analysis of in-patient care. Acta Psychiatr Scand. 2007;116: 36-46.
13. Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry. 2004;65:1076-1083.
14. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006;114:14-20.
15. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand. 2009;120:97-101.
16. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilization in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009;12:317-324.
17. Thomson Healthcare. MarketScan® research databases user guide and database dictionary. Ann Arbor, MI: Thomson Healthcare, Inc; 2007.
18. Ramsey S, Willke R, Briggs A, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8:521-533.
19. Faries DE, Peng X, Obenchain RL. Costs and cost effectiveness analysis using propensity score bin bootstrapping. In: Faries DE, Leon AC, Haro JM, Obenchain RL, editors. Analysis of Observational Health Care Data Using SAS. Cary, NC: SAS Institute; 2010.
20. Faries DE, Nyhuis AW, Ascher-Svanum H. Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc. 2009;7:11.
21. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30: 437-452.
22. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64: 1308-1315.